Skip to main content
PMC home page
Indian Journal of Surgical Oncology logoLink to Indian Journal of Surgical Oncology
. 2010 Aug 7;1(1):19–26. doi: 10.1007/s13193-010-0007-9

Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer

Jean-Marc Nabholtz 1,✉, Marie-Ange Mouret-Reynier 1, Xavier Durando 1, Isabelle Van Praag 1, Béatrice Nayl 1, Jean-Pierre Ferriere 1, Philippe Chollet 1
PMCID: PMC3420988  PMID: 22930614

Abstract

Tamoxifen has been considered for several decades as the standard upfront hormonal therapy for patients with endocrine-sensitive early breast cancer. The efficacy and favorable toxicity profiles of third-generation aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, in advanced disease led to their development in early breast cancer. Recent trial results consistently showed the superiority of AIs over tamoxifen in using the two following therapeutic approaches: either the upfront strategy (randomization of newly diagnosed patients: tamoxifen for 5 years vu AI for 5 years) or the sequencial strategy (randomization of newly diagnosed patients: tamoxifen (2–3 years) followed by AI or the inverse for a total of 5 years vs upfront AI for 5 years).

Despite some common characteristics, a body of evidence on AIs suggests some specific differences between the three agents in terms of efficacy as well as toxicity profiles. Thus, these hormonal agents may not be considered interchangeable in clinical practice. This review will explore available results from AIs trials and will try to define their present role in the upfront adjuvant management of postmenopausal patients with breast cancer.

Keywords: Breast cancer, Adjuvant treatment, Aromatase inhibitors, Anastrozole, Letrozole, Exemestane, Tamoxifen

References

  • 1.Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. doi: 10.3322/canjclin.55.2.74. [DOI] [PubMed] [Google Scholar]
  • 2.Early Breast Cancer Trialists’ Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. doi: 10.1016/S0140-6736(05)66544-0. [DOI] [PubMed] [Google Scholar]
  • 3.Andre F., Slimane K., Bachelot T., et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22:3302–3308. doi: 10.1200/JCO.2004.08.095. [DOI] [PubMed] [Google Scholar]
  • 4.Colozza M., Cardoso F., Sotiriou C., et al. Bringing molecular prognosis and prediction to the clinic. Clin Breast Cancer. 2005;6:61–76. doi: 10.3816/CBC.2005.n.010. [DOI] [PubMed] [Google Scholar]
  • 5.Endogenous HormonesBreast Cancer Collaborative Group Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606–616. doi: 10.1093/jnci/94.8.606. [DOI] [PubMed] [Google Scholar]
  • 6.Allred D.C., Mohsin S.K., Fuqua S.A. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 2001;8:47–61. doi: 10.1677/erc.0.0080047. [DOI] [PubMed] [Google Scholar]
  • 7.Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 1896;2:104–107. doi: 10.1016/S0140-6736(01)72307-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Ring A., Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11:643–658. doi: 10.1677/erc.1.00776. [DOI] [PubMed] [Google Scholar]
  • 9.Wysowski D.K., Honig S., Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med. 2002;346:1832–1833. doi: 10.1056/NEJM200206063462319. [DOI] [PubMed] [Google Scholar]
  • 10.Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529–1542. doi: 10.1093/jnci/88.21.1529. [DOI] [PubMed] [Google Scholar]
  • 11.Segaloff A., Weeth J.B., Meyer K.K., et al. Hormonal therapy in cancer of the breast. 19. Effect of oral administration of delta-1-testolactoneon clinical course and hormonal excretion. Cancer. 1962;15:633–635. doi: 10.1002/1097-0142(196205/06)15:3<633::AID-CNCR2820150327>3.0.CO;2-L. [DOI] [Google Scholar]
  • 12.Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18:3758–3767. doi: 10.1200/JCO.2000.18.22.3758. [DOI] [PubMed] [Google Scholar]
  • 13.Bonneterre J., Thurlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000;18:3748–3757. doi: 10.1200/JCO.2000.18.22.3748. [DOI] [PubMed] [Google Scholar]
  • 14.Bonneterre J., Buzdar A., Nabholtz J.M., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001;92:2247–2258. doi: 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  • 15.Nabholtz J.M., Bonneterre J., Buzdar A., Robertson J.F. Thurlimann B Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer. 2003;39:1684–1689. doi: 10.1016/S0959-8049(03)00326-5. [DOI] [PubMed] [Google Scholar]
  • 16.Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101–2109. doi: 10.1200/JCO.2003.04.194. [DOI] [PubMed] [Google Scholar]
  • 17.Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) — A randomized phase III trial of the EORTC Breast Group. Proc ASCO 23: abs 515, 2004.
  • 18.Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–2746. doi: 10.1200/JCO.1996.14.10.2738. [DOI] [PubMed] [Google Scholar]
  • 19.The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–2139. doi: 10.1016/S0140-6736(02)09088-8. [DOI] [PubMed] [Google Scholar]
  • 20.The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802–1810. doi: 10.1002/cncr.11745. [DOI] [PubMed] [Google Scholar]
  • 21.ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62. doi: 10.1016/S0140-6736(04)17666-6. [DOI] [PubMed] [Google Scholar]
  • 22.ATAC Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100 month analysis of the ATAC trial. http//oncololy/Thelancet.com 2005; DOI:10.1016/S1470-2045(07)70385-6. [DOI] [PubMed]
  • 23.Coates A., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486–492. doi: 10.1200/JCO.2006.08.8617. [DOI] [PubMed] [Google Scholar]
  • 24.Mouridsen H.T., Giobbie-Hurder A., Mauriac L., et al. For the BIG I-98 Collaborative and the International Breast Cancer Study Group Bern, Switzerland. A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat. 2008;69(suppl2):66S. [Google Scholar]
  • 25.Jones S.E., Seynaeve C., Hasenburg C., et al. Results of the first planned analysis of the TEAM (Tamoxifen Exemestane Adjuvant Multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Breast Cancer Res Treat. 2009;69(suppl2):67S. [Google Scholar]
  • 26.Jakesz R., Gnant M., Greil R., et al. Tamoxifen and anastrozole as a sequential strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the ABCSG trial 8. Breast Cancer Res Treat. 2009;69(suppl2):S67. [Google Scholar]
  • 27.Powles T.J., Hickish T., Kanis J.A., et al. Effect of tamoxifen on bone mineral density measured by dual-energy Xray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78–84. doi: 10.1200/JCO.1996.14.1.78. [DOI] [PubMed] [Google Scholar]
  • 28.ATAC Trialists’ Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7(8):633–643. doi: 10.1016/S1470-2045(06)70767-7. [DOI] [PubMed] [Google Scholar]
  • 29.Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619–629. doi: 10.1200/JCO.2005.09.121. [DOI] [PubMed] [Google Scholar]
  • 30.Gnant M., Jakesz R., Mlineritsch B., et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen-bone density subprotocol results of a randomized multicenter trial (ABCSG-12) Breast Cancer Res Treat. 2004;88:S8. [Google Scholar]
  • 31.Cella D., Fallowfield L., Barker P., et al. Quality of life of postmenopausal women in the ATAC (’Arimidex’, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100:273–284. doi: 10.1007/s10549-006-9260-6. [DOI] [PubMed] [Google Scholar]
  • 32.Gorodeski G.I. Update on cardiovascular disease in post-menopausal women. Best Pract Res Clin Obstet Gynaecol. 2002;16(3):329–355. doi: 10.1053/beog.2002.0282. [DOI] [PubMed] [Google Scholar]
  • 33.Ewen M, Gluck S. A woman’s heart: The impact of adjuvant endocrine therapy on cardiovascular health. Cancer; Published online 20 February 2009. [DOI] [PubMed]
  • 34.Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. doi: 10.1001/jama.288.3.321. [DOI] [PubMed] [Google Scholar]
  • 35.Nabholtz J.M., Glogorov J. Cardiovascular safety profiles of aromatase inhibitors: a comparative review. Drug Safety. 2006;29(9):785–801. doi: 10.2165/00002018-200629090-00003. [DOI] [PubMed] [Google Scholar]
  • 36.Seruga B., Tannock I.F. Upfront use of aromatase inhibitors as adjuvant therapy for breast cancer: The emperor has no clothes. J Clin Oncol. 2009;27(6):840–842. doi: 10.1200/JCO.2008.19.5594. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Surgical Oncology are provided here courtesy of Springer

RESOURCES